<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>School of Life Sciences</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8671F71D-01E4-4230-8D7B-CAA74C9A855D"><gtr:id>8671F71D-01E4-4230-8D7B-CAA74C9A855D</gtr:id><gtr:name>New University of Lisbon</gtr:name><gtr:address><gtr:line1>Campus de Campolide</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/17CCF9D8-0A2A-46C8-9E38-16BAC84D9CBC"><gtr:id>17CCF9D8-0A2A-46C8-9E38-16BAC84D9CBC</gtr:id><gtr:name>Helmholtz Association</gtr:name><gtr:address><gtr:line1>Anna-Louisa-Karsch-Strasse 2</gtr:line1><gtr:line4>Berlin</gtr:line4><gtr:line5>10178</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/64DCB3F7-7193-4591-8C5A-B7E20956C06B"><gtr:id>64DCB3F7-7193-4591-8C5A-B7E20956C06B</gtr:id><gtr:name>Insitute of Cybernetics ICIB</gtr:name><gtr:address><gtr:line1>Via Campi Flegrei</gtr:line1><gtr:line2>34 Comprensorio</gtr:line2><gtr:postCode>80078</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9D95AFAF-0F95-473D-8114-00B6A832CE18"><gtr:id>9D95AFAF-0F95-473D-8114-00B6A832CE18</gtr:id><gtr:name>University of Zaragoza</gtr:name><gtr:address><gtr:line1>Departamento de Quimica Organica</gtr:line1><gtr:line2>Facultad de Ciencias</gtr:line2><gtr:line3>Universidad de Zaragoza</gtr:line3><gtr:postCode>50009 Zara</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/DAA8698B-4B18-4A1C-AD5A-4D40A83CD459"><gtr:id>DAA8698B-4B18-4A1C-AD5A-4D40A83CD459</gtr:id><gtr:firstName>Catherine</gtr:firstName><gtr:otherNames>Cecilia</gtr:otherNames><gtr:surname>Berry</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FH006885%2F1"><gtr:id>5BF32995-EF61-4894-9E0D-2BB83699A11C</gtr:id><gtr:title>Multifunctional gold nanoparticles for gene therapy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/H006885/1</gtr:grantReference><gtr:abstractText>A major obstacle in the use of many chemicals for diagnosis or treatment is the lack of tissue specificity. A tag for molecular imaging or a drug-carrying system would have to circulate in the blood stream undetected by the immune system and would have to recognize the desirable target and gives a detectable signal or delivers the drug in it. This NANOTRUCK project intends to develop an innovative kind of multifunctional gold nanoparticles loaded with fluorescent and tumoral markers, cell penetrating peptides and RNAi complementary to the proto-oncogene myc. This biofunctionalization will allow the interaction between NPs and biological systems, ranging from in vitro cultured human cells to in vivo animal models (primitive Hydra and complex vertebrate mouse). This new nanoplatform will allow the targeting and detection of tumor cells and also the study of cellular response against gene tumoral therapy, converting it in a potent tool for the emerging area of theragnostics.</gtr:abstractText><gtr:fund><gtr:end>2012-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2009-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>135742</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>This was an EU funded grant, through the EPSRC. Several groups including us were involved. The grant resulted in a very successful PhD studentship, which was completed and submitted on the 3 year mark. Since completion, 4 papers have been published associated with this grant - 2 original papers and 2 review articles.

In terms of collaborations, two of the original partner groups in Spain and Portugal have remained in contact and we have since collaborated in several projects, including a recently finished BBSRC 2.5 year research grant. 

With regards to impact, several non-science publications were also noted regarding to the work, including for the NHS, Nano Weekly and Materials Today. Such publications demonstrate the interest for broader audience and also illustrate my interest in actively promoting knowledge exchange between different sectors.

I was also selected to give online interviews for several online science schedules, including Magnetic Materials, Applied Physics and the Thought Leader series on News Medical.</gtr:description><gtr:firstYearOfImpact>2011</gtr:firstYearOfImpact><gtr:id>427E75B9-F748-4810-A130-F422485614F9</gtr:id><gtr:impactTypes><gtr:impactType>Societal</gtr:impactType></gtr:impactTypes><gtr:outcomeId>545c9192bc2783.79934658</gtr:outcomeId><gtr:sector>Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>The grant was focused on trying to reduce cancer tumour growth by stopping, or knocking out, one of the main genes involved in tumour cell growth.</gtr:description><gtr:exploitationPathways>The particles were shown to knock down a key cell proliferation gene in HeLa cancer cells, however they should be usable across all cell types. So, I can foresee these NPs being adapted for use in various other cancer growths. In addition, they type of chemistry used to make the NPs (ie. the strong thiol bonds used to attach the siena onto our NP surface) is perfectly adaptable to use for other thiolated fragments on RNA, so many other projects and end uses can be envisaged.</gtr:exploitationPathways><gtr:id>6AD72F38-8790-4BD4-9270-66BA28C0A120</gtr:id><gtr:outcomeId>545c91d2dcbba5.52468294</gtr:outcomeId><gtr:sectors><gtr:sector>Education,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors><gtr:url>http://cordis.europa.eu/result/rcn/140456_en.html</gtr:url></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>915E5D39-125C-4E2F-BE74-14DB9CF3B196</gtr:id><gtr:title>Design of multifunctional gold nanoparticles for in vitro and in vivo gene silencing.</gtr:title><gtr:parentPublicationTitle>ACS nano</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dbc56c6ab2fb8c9a149a58541017829c"><gtr:id>dbc56c6ab2fb8c9a149a58541017829c</gtr:id><gtr:otherNames>Conde J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1936-0851</gtr:issn><gtr:outcomeId>doi_53d01b01bbc4e131</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA4F4005-7F4C-4875-B2CE-89F59074152B</gtr:id><gtr:title>Gold nanoparticle-siRNA mediated oncogene knockdown at RNA and protein level, with associated gene effects.</gtr:title><gtr:parentPublicationTitle>Nanomedicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9037dfe9f77fb05a59d3c3f19f2a6f96"><gtr:id>9037dfe9f77fb05a59d3c3f19f2a6f96</gtr:id><gtr:otherNames>Child HW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1743-5889</gtr:issn><gtr:outcomeId>56ddea0ebaf712.87401541</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE88CD9A-B07D-4458-A4CF-D128F116B8D6</gtr:id><gtr:title>Significance of the balance between intracellular glutathione and polyethylene glycol for successful release of small interfering RNA from gold nanoparticles</gtr:title><gtr:parentPublicationTitle>Nano Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1107f39b7e3bc4c05b41486719aab09"><gtr:id>e1107f39b7e3bc4c05b41486719aab09</gtr:id><gtr:otherNames>McCully M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56ddea0edb00a7.54303495</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6F2A05A-99B7-4D3D-B9D2-EB70240A2ED4</gtr:id><gtr:title>15 years on siRNA delivery: Beyond the State-of-the-Art on inorganic nanoparticles for RNAi therapeutics</gtr:title><gtr:parentPublicationTitle>Nano Today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dbc56c6ab2fb8c9a149a58541017829c"><gtr:id>dbc56c6ab2fb8c9a149a58541017829c</gtr:id><gtr:otherNames>Conde J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56ddea0f061095.12414302</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/H006885/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>A442BF36-F335-483E-9282-F3BB48AC2C47</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Cell biology</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>60EBB420-734E-4DB5-B0F2-65A1115A27F8</gtr:id><gtr:percentage>80</gtr:percentage><gtr:text>Chemical synthesis</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>0B9701E7-D17F-4963-82DA-B3926A65B50A</gtr:id><gtr:percentage>80</gtr:percentage><gtr:text>Biological &amp; Medicinal Chem.</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>D16FDB98-8CBA-4298-8ACD-955DF734E7F5</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Cells</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>